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Abstract
Calpains are calcium-activated proteases that have biomedical and biotechnological poten-
tial. Their activity is tightly regulated by their endogenous inhibitor, calpastatin that binds to
the enzyme only in the presence of calcium. Conventional approaches to purify calpain com-
prise multiple chromatographic steps, and are labor-intensive, leading to low yields. Here
we report a new purification procedure for the human m-calpain based on its reversible cal-
cium-mediated interaction with the intrinsically disordered calpastatin. We exploit the spe-
cific binding properties of human calpastatin domain 1 (hCSD1) to physically capture human
m-calpain from a complex biological mixture. The dissociation of the complex is mediated by
chelating calcium, upon which heterodimeric calpain elutes while hCSD1 remains immobi-
lized onto the stationary phase. This novel affinity-based purification was compared to the
conventional multistep purification strategy and we find that it is robust, it yields a homoge-
neous preparation, it can be scaled up easily and it rests on a non-disruptive step that main-
tains close to physiological conditions that allow further biophysical and functional studies.
Introduction
Calpains (EC 3.4.22.53) are intracellular calcium-activated cysteine proteases with broad endo-
peptidase specificity. Members of the calpain family have been identified in a wide range of
eukaryotic organisms and even in some bacteria [1,2]. In Mammalia, these proteins are
reported to be involved in various key physiological processes such as cell mobility, embryo-
genesis, apoptosis and various signal transduction pathways [1]. So far, 15 human genes are
known to encode calpain-like protease domains [2]. The best studied calpain isoforms are the
ubiquitously expressed μ-calpain and m-calpain, which require micromolar and millimolar
concentrations of calcium for their enzymatic activation, respectively. X-ray crystallographic
analyses have identified their unique activation mechanism: they are heterodimers consisting
of an 80kDa large subunit (consisting of 4 domains) and a 30kDa small subunit (consisting of
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2 domains) that undergo major conformational rearrangements upon binding multiple cal-
cium ions [3,4]. Since calpain activity is involved in various pathophysiological phenomena,
the regulation of calpain is crucial for proper cell functioning. Besides calcium, calpain activity
is regulated by an endogenous inhibitor, calpastatin that can only bind to the calcium-activated
conformation. Calpastatin is an intrinsically disordered protein (IDP) composed of four inhib-
itory domains, each capable of inhibiting the enzyme [5]. Each inhibitory domain consists of 3
subdomains (region A, B and C) that only acquire a stable conformation upon binding to the
calcium-activated calpain surface.
Increased intracellular calcium levels lead to hyperactivation of calpain and are associated
with a large variety of pathologies: m-calpain dysregulation is tightly associated with human
diseases such as cancer, cataract and neurodegenerative syndromes like Alzheimer’s disease
[6]. Calpains are thus of great medical and therapeutic interest, and there is a need for calpain-
specific inhibitors that will not affect other cysteine proteases like cathepsin B and cathepsin L.
To better understand the structure-function relationship and to implement that knowledge
to design efficient drugs to cure the diseases, it is necessary to produce calpain at sufficient
quantity and quality. Active human and rat μ-calpain have been recombinantly expressed and
purified using Escherichia coli and the baculovirus expression systems [7,8]. Recombinant rat
m-calpain has been produced on large scale in E. coli [9,10], while a recombinant version of
human m-calpain has been successfully expressed in E. coli by co-expressing the hexahistidine-
tagged large subunit with a truncated small subunit [11]. Despite the application of affinity-
tags to facilitate the specific isolation of these proteins, the methodology to purify them is time
consuming as it consists of multiple chromatographic steps, which compromises the protein
yield. To address the problems, several affinity-based chromatographic methods utilizing
immobilized substrates (e.g. casein), inhibitors and antibodies have been reported [7,12–15].
Still, these methods either have the risk of co-purifying of proteins that show calcium-depen-
dent binding to the immobilized substrates or require pre-chromatographic steps in the sam-
ple preparation[9,14,16]. The most recently reported purification strategy for recombinant
human m-calpain requires four chromatographic steps to obtain pure and active enzyme [11].
Here, we describe the development of a single-step affinity chromatography strategy by
exploiting the binding properties of the intrinsically disordered human calpastatin domain 1
(hCSD1) to isolate recombinantly produced human m-calpain and selected variants thereof
from E. coli lysate.
Materials and methods
Expression vectors and mutagenesis
The expression plasmids of the wild type (WT) 80kDa human m-calpain large subunit
(CAPN2 in pET24b(+)) and the truncated 23kDa small subunit (CAPNS1ΔG2 in pACpET)
were generously provided by Dr. Hiroyuki Sorimachi (Tokyo Metropolitan Institute of Medi-
cal Science, Japan)[11]. An inactive m-calpain mutant large subunit, in which the cysteine at
position 105 was mutated to alanine (C105A), was generated from the wild type with the
QuickChange Site-Directed Mutagenesis kit (Agilent Technologies) using oligonucleotides
5’-ggagccctgggtgacgcctggctgctggcagcc-3’and 5’-ggctgccagcagccaggc
gtcacccagggctcc-3’ (the C105A nucleotide substitution is underlined). The successful
mutagenesis was confirmed through DNA sequencing (VIB genetic sequencing facility). The
expression plasmid of the human calpastatin domain 1 (hCSD1; corresponding to region
A137-K277 of the human calpastatin amino acid sequence) was obtained from Dr. Masatoshi
Maki (Institute for Virus Research, Japan)[17]. An N-terminal glutathione S-transferase-
tagged (GST-tagged) version of hCSD1 was expressed from a synthetic gene that was
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constructed in the pGEX-4T-1 (GE Healthcare Life Science) vector by GeneArt AG (Life
Technologies).
Expression of the Wild Type (WT) and inactive mutant human m-calpain
The large and small subunit of WT human m-calpain were co-expressed in Escherichia coli
BL21(DE3) (Invitrogen)[11]. The bacterial cells were grown in 2L baffled flasks at 27˚C and
180 rpm in a minitron incubator shaker (Infors-HT) until the optical density at 600nm
(OD600) reached 0.6 to 0.8. The protein expression was induced by the addition of 0.2mM iso-
propyl β-D-1-thiogalactopyranoside (IPTG) and continued growth for 6h at 22˚C while shak-
ing at 180rpm.
The C105A variant of the large subunit was co-expressed with the truncated small subunit
in E. coli BL21(DE3) and the cells were initially grown at 30˚C and 180 rpm shaking until the
OD600 reached 0.3. The temperature was then changed to 16˚C while shaking at 180 rpm until
the OD600 reached 0.6 to 0.8. The protein expression was induced by adding 0.25mM IPTG
and the induced cells were incubated for 16h at 16˚C while shaking at 180 rpm.
The C105A large subunit of m-calpain was expressed in E. coli BL21(DE3). The bacterial
culture was initially grown at 30˚C, 180rpm until OD600 reached 0.6. The protein expression
was induced by adding 0.2mM IPTG and continued growth at 16˚C for only 6h while shaking
at 180 rpm.
Production of hCSD1 and its variations
The hCSD1 expression plasmid was transformed into the E. coli BL21-AI strain (Invitrogen).
The transformants were grown in ampicillin-containing (100 μg/mL) Luria-Bertani broth (LB)
at 37˚C with vigorous shaking at 180 rpm. The protein expression was induced with 1mM
IPTG and 0.2% L-arabinose at OD600 of ~0.5 to 0.8, and continued shaking for 4 hours a 180
rpm, 37˚C.
The induced cells were harvested and centrifuged at 5000g for 15 minutes. The pellets were
re-suspended in lysis buffer containing 20mM Tris-Cl pH 7.5, 0.1mM ethylenediaminetetra-
acetic acid (EDTA), 25mM NaCl, 2mM 1,4-dithiothreitol (DTT), 2mM 4-(2-aminoethyl)ben-
zenesulfonyl fluoride hydrochloride (AEBSF) and 5mM benzamidine. The suspended cells
were heated for 10 minutes at 99˚C, followed by centrifugation at 21191g for 45 minutes. The
supernatant was filtered via a 0.22μm polyethersulfone membrane and applied to a Hitrap
DEAE FF anion exchange column (GE Healthcare) equilibrated with buffer containing 20mM
Tris-Cl pH 7.5, 0.1mM EDTA, 2mM DTT at flow rate of 1ml/min. hCSD1 was eluted from the
column using a step elution of 150mM NaCl for 10 column volumes in 20mM Tris-Cl pH 7.5,
0.1mM EDTA, 2mM DTT. The purified protein was applied to a Superdex 75 gel filtration col-
umn equilibrated with 30mM 3-(N-morpholino)propanesulfonic acid (MOPS) pH 7.5, 1mM
tris(2-carboxyethyl)phosphine (TCEP).
The GST-tagged hCSD1 was expressed in E.coli BL21(DE3) at 37˚C. The protein expres-
sion was induced with 1mM IPTG at an OD600 of 0.6–0.8, followed by 4 hours at 37˚C and
180rpm. The cells were harvested by centrifugation (at 5000g for 15 minutes) and re-sus-
pended in phosphate-buffered saline (PBS) supplemented with Complete1 protease inhibitor
tablets (Roche Diagnostics), followed by a pulse sonication (2 seconds on, 5 seconds off) for 2
minutes (60% amplitude) using 130Watt Ultrasonic Processor (Sonics & Materials, INC.).
The suspended cells were centrifuged at 21191g for 30 minutes. The lysate was filtered
(0.22μm polyethersulfone membrane) and applied to a GSTrap FF column (GE Healthcare)
equilibrated with PBS. The protein was eluted by a step elution of 10 mM reduced glutathione
in 50 mM Tris-Cl pH 8.0.
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The biotinylation of hCSD1 was accomplished using EZ-Link™ NHS-PEG4-Biotinylation
kit (Pierce Biotechnology) according to the manufacturer’s instructions. The integrity of the
biotinylated sample was verified by SDSPAGE analysis. To quantify the extent of the biotinyla-
tion we used the absorbance-based 2-(40-hydroxyazobenzene) benzoic acid (HABA) dye assay
that was provided by the manufacturer of the biotinylation kit (Pierce Biotechnology).
Conventional purification of calpain
The established purification procedure for recombinantly produced human m-calpain com-
prises several chromatographic steps and was performed as described by Hata et al. (2012)
with some minor modifications as follows: (1) 0.3 mM AEBSF was used as a protease inhibitor
in the lysis buffer instead of 0.3 mM PMSF; (2) the DEAE-toyopearl and the MonoQ HR10/10
anion exchange columns were substituted by a Hitrap DEAE FF and a MonoQ 4.6/100 PE
anion exchange columns (GE Healthcare), respectively.
Affinity purification (AF) of calpain
All purification procedures were performed at 4˚C. The induced cells were harvested and cen-
trifuged at 5000g, 15 minutes. The pellet was re-suspended in lysis buffer containing 30mM
MOPS pH7.5, 1mM EDTA, 1mM TCEP and supplemented with Roche protease inhibitors
cocktail (which does not contain irreversible Cys-protease inhibitors). The cells were lysed by
sonication using a series of short pulse (2 seconds on-5 seconds off, 80% amplitude) with
130Watt Ultrasonic Processor (Sonics & Materials, INC.). Then we loaded 2 mg of biotinylated
hCSD1 (b-hCSD1) onto a 1ml Streptavidin HP column (GE Healthcare) equilibrated with
30mM MOPS pH7.5, 1mM TCEP at the flow rate of 0.1 ml/min using an Akta Avant (GE
Healthcare). The b-hCSD1-immobilized column (affinity column) was washed with buffer
containing 30mM MOPS pH7.5, 200mM NaCl, 5mM CaCl2, 1mM TCEP for 5 column vol-
umes. The calpain lysate was supplemented with 200mM NaCl and 5mM CaCl2 immediately
before applying it to the affinity column at the flow rate of 0.5ml/min. The column was washed
with buffer containing 30mM MOPS pH7.5, 200mM NaCl, 5mM CaCl2, 1mM TCEP and the
protein was eluted by a step elution with 20mM MOPS pH 8.0, 1mM TCEP and 10mM EDTA.
Enzymatic calpain activity assay
The proteolytic activity of WT m-calpain and inactive C105A-calpain was monitored by using
the fluorogenic substrate N-succinyl-Leu-Leu-Val-Tyr-AMC (ENZO Life Sciences). The
lyophilized substrate was dissolved in 100% dimethyl sulfoxide (DMSO) and diluted in reac-
tion mixture (200μl in total volume) containing 20mM MOPS, 1mM TCEP, and 3mM CaCl2
to a series of concentrations from 4 to 80 μM. At last, 150nM enzyme was added to the reaction
mixture. The enzyme kinetics were measured at 30˚C for 10 minutes; fluorescence of the prod-
uct was recorded at excitation and emission wavelengths of 380 and 460nm, respectively, using
a Biotek Synergy MX plate reader. The kinetic data were derived by performing a non-linear
least square fit of the experimental data using Michaelis-Menten equation and Graphpad
Prism 7.
Circular dichroism analysis
The far-UV circular dichroism (CD) spectrum of C105A-calpain was recorded using a Jasco J-
715 CD spectropolarimeter equipped with a PTC 423S Peltier element. The protein concentra-
tion was 2μM in 20mM MOPS pH 7.5. The far-UV spectrum of the protein was recorded in a
high-quality quartz cuvette of 1mm path-length at the wavelength from 260nm to 200nm, at
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scanning speed of 20nm/min, a response time of 2 seconds and a spectral bandwidth of 1nm.
The final CD spectrum was the result of 3 accumulated scans.
The secondary structure content based on the CD spectrum was derived and compared to
the deposited crystal structure of the calcium-free human m-calpain (PDB ID: 1KFU)[3] using
the BeStSel web server (available at http://bestsel.elte.hu) [18]. The scaling factor was set to 0.1
in order to generate the best fitted data with the lowest possible normalized root-mean-square
deviation (NRMSD) score.
Interaction analysis of GST-hCSD1 and biotinylated-hCSD1 to calpain
using bio-layer interferometry
To monitor interaction of calpain with calpastatin, we immobilized GST-hCSD1 and b-
hCSD1 at a final concentration of 10 μg/ml to anti-GST and streptavidin (SA) biosensors,
respectively. The E.coli lysate containing expressed C105AΔG2 was diluted 10x, 100x and
1000x and loaded to the hCSD1-immobilized sensors. As negative controls, we used the non-
functionalized sensors that were dipped in the C105AΔG2 lysate for the association phase. In
case of the anti-GST biosensor, a biosensor with immobilized GST was used as a second refer-
ence. The signal from these control samples was subtracted during the data processing. The
experiments run at 30˚C, at agitation of 1000 rpm, were recorded by the ForteBio data acquisi-
tion software version 7.1, and analyzed by the data analysis software of the same package.
Bioinformatics sequence analysis
We assembled a comprehensive data set of 20 experimentally validated homologous amino
acid sequences of CSDs by performing a PSI-BLAST against the non-redundant (NR) protein
set of NCBI [19]. The query sequence was the first domain (residues 137–277; hCSD1) of the
human calpastatin (UniProt ID: P20810). The data set of retrieved sequences covered the ver-
tebrate taxonomic groups of mammals, birds and amphibians. We generated a multiple
sequence alignment (MSA) with MAFFT and used the MSA as input for the sequence- and
disorder conservation analysis carried out with the local version of the DisCons tool[20,21].
Briefly, DisCons calculates the position-specific sequence- and disorder conservation scores
based on a multiple sequence alignment. DisCons was used with default parameters, namely
predicting disorder with IUPred, and quantifying the sequence conservation with Jensen-
Shannon divergence [21]; the maximum allowed fraction of gaps for a position was set to 0.6.
The conservation trajectories were plotted using R.
Results
Selecting an eligible hCSD1 immobilization strategy
Initially, we chose glutathione S-transferase (GST) as an affinity-tag to immobilize GST-
hCSD1 to a GSTrap column for various reasons, in particular because (i) the CAPN2-con-
structs contain a C-terminal his-tag; (ii) GST is a well-folded protein that is easily produced
and does not interact with calpain; (iii) GST is unlikely to interfere with the interaction of
hCSD1 with calpain; (iv) it is possible to remove the GST tag by thrombin cleavage to produce
the calpain-calpastatin complex; and (v) GST can be used as a negative control for detailed
interaction studies. The second choice was the chemical biotinylation of hCSD1 followed by
its immobilization to streptavidin.
hCSD1 was easily produced with high purity (based on SDS-PAGE analysis) and in high
quantity (Fig 1A). The protein appeared as a 23kDa band on an SDS-PAGE gel due to its aber-
rant electrophoretic mobility because of its disordered amino acid composition (see section
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‘sequence analysis’), which has been reported in literature [1]. As expected, the GST-hCSD1
variant expressed well in E.coli and was purified by the GSTrap affinity chromatography
(Fig 1B).
The chemical biotinylation of hCSD1 (b-hCSD1) was successful and yielded 2 mol biotin
per mol of hCSD1. In addition, we verified the integrity of b-hCSD1 via SDSPAGE (Fig 1B).
Even though the interaction of hCSD1 and calpain has been well described in literature
using various techniques, we wanted to probe whether the GST-tag and biotinylation would
hamper the binding capacity of hCSD1. Hence, we investigated whether immobilized hCSD1
is capable of capturing calpain from bacterial lysate using bio-layer interferometry (BLI). In
both cases, the binding signals were recorded (Fig 2) and lead us to conclude that neither the
biotinylation nor the GST-tag impedes the binding capability of hCSD1 to capture calpain
from a biologically complex mixture. Yet, the dissociation phases of the binding curves (Fig 2)
Fig 1. Expression and purification of (A) hCSD1, (B) GST-hCSD1 and b-hCSD1. NI: Non-induced; I:
Induced; FT: Flow-through of hCSD1 lysate after anion exchange chromatography; AXN, GF: hCSD1 after
anion exchange chromatography and gel filtration, respectively; GSTrap: GST-hCSD1 at 45kDa band after
GSTrap affinity chromatography.
https://doi.org/10.1371/journal.pone.0174125.g001
Fig 2. Binding kinetics of hCSD1 with C105AΔG2-containing lysate with 2 different immobilization
strategies. Panel A and B show the binding of biotinylated-hCSD1 and GST-hCSD1, respectively, to the
1000-fold diluted lysate that contained recombinantly expressed C105AΔG2.
https://doi.org/10.1371/journal.pone.0174125.g002
Purification of human m-calpain by affinity chromatography
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suggest that the binding of m-calpain to biotinylated hCSD1 is almost irreversible as compared
to the GST-immobilized hCSD1 construct. This observation could either be explained by dif-
ferences in protein flexibility due to the tag position (GST is N-terminally fused through a
linker, while biotin is coupled to primary amines of lysine side chains), or by the physicochem-
ical differences between the biosensors used. Nonetheless, since this calcium-mediated
hCSD1-to-calpain binding can be abolished with EDTA to chelate calcium [22], we wish to
exploit these binding characteristics to selectively isolate m-calpain.
As we found that the GST-tag and biotinylation do not hamper the binding of hCSD1 to
calpain, our initial strategy comprised of the immobilization of hCSD1 with an N-terminal
GST-tag followed by the application of the crude calpain-containing bacterial lysate in the
presence of calcium to the immobilized GST-hCSD1 and finally the elution of the calpain het-
erodimer using a chelating agent like EDTA. Unfortunately, this initial strategy failed since
GST and GST-hCSD1 were co-eluted with the target protein upon the application of EDTA.
Although it might be possible that GST and/or GST-hCSD1 were proteolyzed by calpain activ-
ity, we established that the elution of GST by EDTA also occurs in the absence of calpain. For
this reason, we decided to implement chemically biotinylated hCSD1 as our immobilization
strategy.
Production and purification of calpain
Both WT and C105A-calpain expressed well in E.coli (Fig 3). It was observed that the solubility
of the protein could be improved by expressing the protein at low temperature, preferably
16˚C. Although it was previously reported that 5.8mg of purified m-calpain could be obtained
from 1-liter E. coli culture [11], the maximum yield that we could reach was 1mg/L bacterial
culture for WT-calpain and 0.4 mg/L bacterial culture for C105A-calpain by the conventional
multistep purification method. By applying the affinity purification (AF) with b-hCSD1, we
were able to increase the production yield at least 2-fold, in which 2mg of WT and 1mg of
C105A-calpain were obtained and the production time was significantly reduced from 3 days
to 1 day. Furthermore, despite applying only two steps instead of four, the sample purity was
identical in case of the C105A-calpain as evidenced by SDS-PAGE (Fig 3B). In the presence of
calcium, autolysis does not happen with inactive C105A-calpain, but the protein solution grad-
ually shows the appearance of aggregates. This aggregation might prevent the interaction of
C105A-calpain with the affinity column and might reduce the purification yield. Hence, it is
necessary to speed up the purification process upon the addition of calcium. The situation is
different with WT-calpain, which undergoes autolysis, two additional bands of the small sub-
unit appeared at around 17kDa and 20kDa (Fig 3A). To confirm that these are autolysis prod-
ucts of the small subunit, one will need to run mass spectroscopy experiments, which has not
been done within the framework of our study. This autolysis adds to the heterogeneity of the
WT calpain sample (Fig 3A), which renders it less amenable for biophysical studies, yet it still
useful for enzymatic or biological studies (e.g. characterization of calpain inhibitors) (see next
section). The C105A inactive calpain mutant is purified as a highly homogeneous sample (Fig
3B) of sufficient quality for in depth biophysical studies.
Characterization of the purified m-calpain for biophysical studies
We compared the performance of the two purification methods by analyzing the enzymatic
activity of the calpain samples. The enzyme kinetic parameters of the purified WT-calpain
were derived from the Michaelis-Menten plot (Fig 4) and summarized in Table 1. The data
show that the affinity of the enzyme purified by AF to the SUC-LLVY-AMC substrate is lower
than that of the conventionally purified one. Following that, the rate of the reaction and the
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specific activity of the affinity purified enzyme are decreased by about 20% as compared to the
conventionally purified protease. This is probably due to the partial proteolytic degradation
that we observed for the small subunit. Indeed, Elce and co-workers reported that the small
subunit truncation could interfere with the formation of a stable and active heterodimer [23].
Likewise, Edmunds and coworkers (1991) showed that, when exposed to calcium, the 80kDa
Fig 3. Expression and purification of WT- (A) and C105A- (B) calpain by conventional and AF
methods. NI: Non-induced; I: Induced; DEAE, MonoQ: anion exchange chromatography using
diethylaminoethyl and MonoQ column; Histrap: immobilized metal affinity chromatography; GF: gel filtration;
AF: immobilized b-hCSD1 affinity chromatography.
https://doi.org/10.1371/journal.pone.0174125.g003
Purification of human m-calpain by affinity chromatography
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large subunit and the 30kDa small subunit are rapidly cleaved to 78 kDa and 18 kDa fragments
and that this 78kDa/18kDa form of calpain retains 80% if its enzymatic activity [24]. Similarly,
the observed small subunit degradation for the WT enzyme (Fig 3A) is likely to explain the
reduction of the specific activity with 20% (Table 1) in our study.
Nonetheless, for structural studies the inactive C105A calpain mutant has been preferred to
avoid any heterogeneity arising from autoproteolysis [10]. As expected, the C105A-calpain
showed no enzyme activity. Therefore, the quality of the purified C105A-calpain from AF was
confirmed by far-UV CD spectroscopy (Fig 5). The secondary structure content estimated
from the wavelength spectrum is in agreement with that derived from the crystal structure
(Table 2). The experimental data was fitted (with an RMSD of 0.115 and an NRMSD of
0.02528) and showed that the protein structure contains a large portion of helix (about 30%)
and β-strand (about 30%).
The fact that we observed a single elution peak at an apparent molecular weight of 125 kDa
with an analytical gel filtration whereby SDSPAGE revealed the presence of both the large and
small subunit, in combination with the CD-based secondary structure estimate of the C105A-
calpain, confirmed that the protein was purified as a well-folded heterodimer that is suitable
for biophysical studies (Fig 3B).
In addition, we could establish with BLI that the purified C105A-calpain from the AF
method interacts with GST-immobilized hCSD1 with a KD of 1.7 nM, which is in agreement
with the KD-value reported in literature [5].
Purification of the large and the small subunit of human m-calpain by the
AF method
Herewith we also provide the evidence that the hCSD1-based affinity purification strategy can
be used to capture fragments or individual domains of calpain. This is due to the modular
structure of the binding motifs of hCSD1. To this end, we purified the 80 kDa large subunit
Fig 4. Michaelis-Menten plot of the WT calpain purified by conventional method (A) and affinity method (B).
https://doi.org/10.1371/journal.pone.0174125.g004
Table 1. Comparison of the kinetic parameters of the enzyme purified by two methods.
Km (μM) Vmax (nM.s-1) Kcat(s-1.10−3) Kcat/Km (μM-1.s-1. 10−3) Specific Activity (nmol.s-1.mg-1)
AF 29.32 ± 5.66 1.708 ± 0.233 12 ± 1 41.3 ± 2.6 0.112 ± 0.014
Conventional method 20.54 ± 2.28 2.262 ± 0.209 15 ± 2 73.2 ± 4.6 0.148 ± 0.015
https://doi.org/10.1371/journal.pone.0174125.t001
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(Fig 6A) and the 21 kDa domain VI (Fig 6B) of human m-calpain. In case of domain VI, we
noticed that a considerable amount of protein remains in the flow-through fraction, which
suggests that the column was saturated and was unable to trap more proteins. Nonetheless,
our method also enables the single-step purification of individual subunits or domains of
calpain.
Sequence analysis of hCSD1 for general applicability of the new affinity
purification strategy
We also performed a comparative sequence analysis to provide indirect evidence for the speci-
ficity of the disordered binding regions of calpastatin and to assess the possible generality of
the affinity principle developed. We collected a comprehensive dataset of homologous calpas-
tatin domain sequences (CSD1 to 4), and with the help of DisCons [25] we quantified the con-
servation of both the amino acid sequence, and the structural disorder of the protein (Fig 7).
Interestingly, the three binding segments of all CSDs (region A, B and C) are significantly
Fig 5. Far-UV CD spectrum of the C105A-calpain purified by AF method.
https://doi.org/10.1371/journal.pone.0174125.g005
Table 2. Estimated secondary structure content (%) of the CD experimental curve (A) and the 1KFU.
pdb crystal structure (B) using the BeStSel web server.
A B
Helix 1 (regular) 19.8 18.6
Helix 2 (distorted) 9.2 11.8
Antiparallel 1 (left-twisted) 2.7 0.4
Antiparallel 2 (relax) 9.3 5.1
Antiparallel 3 (right-twisted) 12.0 8.2
Parallel 5.9 0.4
Turn 10.4 11.3
Others 30.8 44.3
https://doi.org/10.1371/journal.pone.0174125.t002
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more conserved across the investigated species than the linker regions between them, and dis-
order conservation is also peaking at these binding segments. Interestingly, the sequence is less
conserved than disorder within the linker regions. This is in accordance with earlier studies
that disordered binding regions, and specifically Molecular Recognition Features (MoRFs)
have relatively higher sequence conservation than their disordered flanking regions. In con-
trast, sequence conservation is generally lower than the conservation of disorder at protein
Fig 6. Coomassie-stained SDS-PAGE analysis of the calpain large subunit (A) and domain VI (B)
that were purified by our new affinity method. M: Molecular weight marker proteins; AF: affinity
chromatography; GF: gel filtration; NI: non-induced; I: induced; FT: flow through after affinity chromatography.
https://doi.org/10.1371/journal.pone.0174125.g006
Fig 7. Sequence- and disorder conservation profile of CSDs. The conservation of both the amino acid
sequence (blue) and structural disorder (red) of CSD was quantified by considering a comprehensive set of
homologous vertebrate CSD sequences covering mammals, birds and amphibians. The two anchoring
regions (A and C) and the inhibitory segment (B) are shaded in grey.
https://doi.org/10.1371/journal.pone.0174125.g007
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chains whose main functional role is to act as flexible linkers [25–27]. These findings demon-
strate that the amino acid sequence of the binding segments of CSDs is highly conserved,
which suggests that calpastatins of various species might be interchangeable in the purification
of calpains.
Discussion
Our work endorses the view that the conventional scheme of purifying recombinant human
m-calpain is time consuming, labor intensive and requires different chromatographic resins.
Despite a terminal His-tag, it requires at least 3 consecutive chromatographic steps to purify
the protein, as a single IMAC step resulted in substandard quality protein samples. Other affin-
ity purification schemes in literature either require pre-preparation steps such as antibody gen-
eration, or protein enrichment [12,28], or they have the risk of co-purifying other proteins in a
calcium dependent manner [15]. Among them, Anagli and coworkers described a similar
method to our newly devised approach to purify calpain from crude extracts of human eryth-
rocyte and bovine kidney or heart by using calpastatin fragments [12]. So far, this method has
not been used for purifying recombinant human m-calpain expressed in E. coli and it com-
prises an anion exchange chromatography before the peptide-affinity purification. Therefore,
we have developed a new and simple affinity purification by taking advantage of the binding
specificity of hCSD1.
Even though the BLI data confirmed that a GST-tag or biotinylation can be used for hCSD1
immobilization, we observed that the GST-hCSD1 co-eluted with the target protein in an
EDTA dependent manner, implying that the interaction of GST-glutathione is disrupted by
chelating agents (i.e., EDTA). Therefore, we resorted to chemical biotinylation of hCSD1 for
immobilization, an approach that proved efficient for the single-step affinity purification.
Although it was not directly observed by us, chemical biotinylation of hCSD1 might affect its
binding properties because it occurs at the primary amines of the protein (i.e. the N-terminus
and the lysine residues). A more controlled and elegant way to biotinylate hCSD1 would be to
employ the BirA ligase in order to site-specifically modify the lysine of the avi-tag, a 15 amino
acid peptide that can be fused to the target protein [29]. Another option would be to use the
sortase labeling reaction to label the protein of interest with a biotinylated peptide [30]. Alter-
native immobilization strategies could rely on activated resins, such as such as the popular
cyanogen bromide- or N-hydroxysuccinimidyl chloroformate-activated resins for the covalent
attachment of the protein using the primary amine coupling.
One potential limitation to the approach that we present here may be manifested in the
autoproteolysis of active calpain, as even an attempt to pre-incubate hCSD1 with calpain lysate
did not remove autoproteolysis. Even so, the ability to purify human m-calpain variants (wild-
type and inactive mutant) and its domains with a purity that is eligible for biological and bio-
physical studies by a single-affinity chromatography step is the major advancement thanks to
our method. Furthermore, it enables to isolate calpain directly from biological samples, which
offers new avenues for studying the enzyme under physiological conditions, for example in its
native post-translationally modified form.
Since IDPs in general are susceptible to protease degradation [31], treatment with general
protease inhibitors might be needed for the efficient use of IDPs in such a strategy. For the tar-
get protein (a proteolytic enzyme as in our case), this could be a complicating factor. Yet, we
did not experience any problems by including general protease inhibitors during our purifica-
tion. Additionally, the functionalized b-hCSD1 stationary phase could be reused for several
subsequent chromatographies, at least when it was stored with 20% EtOH and protease
inhibitors.
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Conclusion
In this study we have described a single-step affinity chromatography to purify recombinant
human m-calpain, by exploiting the binding properties of its intrinsically disordered inhibitor,
calpastatin. Compared to other established purification procedures, our method has several
advantages: (i) it requires considerably less time investment (a single chromatographic step
suffices); (ii) it can also be easily applied to purify individual calpain domains; (iii) the purity
and the integrity of the purified protein is sufficient for structural biology studies; (iv) high
throughput optimization of this method is possible through BLI (e.g. with different calpastatin
variants, different screening conditions. . .); and (v) it enables rapid isolation directly from bio-
logical samples. The drawback of our method is the pre-activation of calpain and the subse-
quent autoproteolysis during purification in the case of the active enzyme. Although the
specific activity of the WT enzyme purified by our newly devised method is somewhat lower
than that resulting from the conventional purification method, it is definitely suitable for fur-
ther structural and functional studies.
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